keyword
MENU ▼
Read by QxMD icon Read
search

Adalimumab

keyword
https://www.readbyqxmd.com/read/27913244/higher-risk-of-hospitalization-and-serious-infection-among-patients-with-ulcerative-colitis-treated-with-adalimumab-compared-with-infliximab-in-a-nationwide-study
#1
Siddharth Singh, Nynne Nyboe Andersen, Mikael Andersson, Edward V Loftus, Tine Jess
BACKGROUND & AIMS: We compared the effectiveness and safety of infliximab and adalimumab in biologic-naïve patients with ulcerative colitis (UC), in a nationwide register-based propensity score-matched study of patients in Denmark. METHODS: We collected data from 1719 adults with UC, 15-75 years old, in Denmark who were treated with either infliximab or adalimumab as their first biologic agent. We compared rates of all-cause hospitalization, UC-related hospitalization, major abdominal surgery, and serious infections after a variable 2:1 propensity score matching, accounting for baseline clinical characteristics, disease severity, healthcare use, and use of UC-related medications...
November 29, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27910149/editorial-adalimumab-or-infliximab-as-monotherapy-or-in-combination-with-an-immunomodulator-in-the-treatment-of-crohn-s-disease
#2
EDITORIAL
B Christensen, M P Sparrow
No abstract text is available yet for this article.
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27909436/evaluation-of-anti-inflammatory-effects-of-steroids-and-arthritis-related-biotherapies-in-an-in-vitro-coculture-model-with-immune-cells-and-synoviocytes
#3
Mélissa Noack, Ndiémé Ndongo-Thiam, Pierre Miossec
BACKGROUND: During rheumatoid arthritis (RA), steroids and biotherapies are used alone and combined. Efficacy has been established in clinical trials but their differential effects at the cellular level are less documented. The aim was to study these cellular effects using an in vitro model with synoviocytes interacting with peripheral blood mononuclear cells (PBMC) to reproduce the interactions in the RA synovium. METHODS: Activated-PBMC were cocultured with RA synoviocytes during 48 h...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27908311/obesity-decreases-clinical-efficacy-and-levels-of-adalimumab-in-patients-with-ankylosing-spondylitis
#4
José Rosas, Francisca Llinares-Tello, José Miguel Senabre-Gallego, Xavier Barber-Vallés, Gregorio Santos-Soler, Esteban Salas-Heredia, Ana Pons Bas, Catalina Cano Pérez, Mario García-Carrasco
OBJECTIVES: Obesity can be a factor that affects response to anti-TNF drugs. However, studies on patients with ankylosing spondylitis (AS) are rare. We aimed to determine whether obesity affects serum levels of adalimumab (ADL), and immunogenicity and clinical efficacy of the drug in patients with AS. METHODS: A cross-sectional study on 57 patients with axial AS receiving ADL was conducted. They received DMARD per standard of care at their rheumatologist's discretion...
November 13, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27907269/remission-rates-with-tofacitinib-treatment-in-rheumatoid-arthritis-a-comparison-of-various-remission-criteria
#5
Josef S Smolen, Daniel Aletaha, David Gruben, Samuel H Zwillich, Sriram Krishnaswami, Charles Mebus
OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Throughout tofacitinib clinical studies, a 28-joint Disease Activity Score (DAS28)-based analysis was used to assess outcomes. In this study, remission rates by various remission criteria were evaluated across five Phase 3 randomized controlled studies. METHODS: Tofacitinib was dosed 5 or 10 mg twice daily (BID), either as monotherapy, or with background methotrexate or other conventional synthetic disease-modifying antirheumatic drugs (DMARDs)...
December 1, 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/27904284/eruptive-benign-melanocytic-nevi-formation-following-adalimumab-therapy-in-a-patient-with-crohn-s-disease
#6
Ik Jun Moon, Chong Hyun Won, Mi Woo Lee, Jee Ho Choi, Sung Eun Chang
No abstract text is available yet for this article.
December 2016: Annals of Dermatology
https://www.readbyqxmd.com/read/27900937/post-authorization-changes-in-the-safety-and-efficacy-assessment-recommended-indications-and-drug-quality-profile-of-adalimumab-a-chronological-overview
#7
Gergely Iványi, Romána Zelkó
OBJECTIVE: The intention of the present study was to demonstrate the postauthorization changes of adalimumab (European trade name: Humira), evaluating the variations in its safety, efficacy, and quality profile. METHODS: Type-II, major variations of the Summary of Product Characteristics (SmPC) from September 8, 2003 to November 19, 2015, were analyzed, which, according to Commission Regulation (EC) No. 1234/2008, have to reflect changes that may have a significant impact on the safety, efficacy, or quality profile of a medicinal product...
November 30, 2016: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27899263/adalimumab-dose-escalation-is-effective-and-well-tolerated-in-crohn-s-disease-patients-with-secondary-loss-of-response-to-adalimumab
#8
Nicolas Duveau, Maria Nachury, Romain Gerard, Julien Branche, Vincent Maunoury, Medina Boualit, Pauline Wils, Pierre Desreumaux, Benjamin Pariente
BACKGROUND: Although adalimumab is effective in Crohn's disease, most patients experience a loss of response over time. The aim of the present study was to evaluate efficacy and safety of adalimumab dose escalation and identify predictors of a clinical response in Crohn's disease patients with a secondary loss of response. METHODS: We performed a retrospective and observational study including all Crohn's disease patients who underwent dose escalation of adalimumab after a secondary loss of response from 2007 to 2015...
November 14, 2016: Digestive and Liver Disease
https://www.readbyqxmd.com/read/27893546/cutaneous-vasculitis-in-a-patient-with-crohn-s-disease-treated-with-adalimumab
#9
Didia B Cury, Alexandre W S de Souza, Giovanni A Vianna, Danilo Odashiro, Alex Farias, Alan C Moss
No abstract text is available yet for this article.
November 22, 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27891490/is-optimal-management-of-recurrent-aphthous-stomatitis-possible-a-reality-check
#10
REVIEW
Shesha Prasad Ranganath, Anuradha Pai
Recurrent Aphthous Stomatitis (RAS) is a condition in which aphthous ulcers repeatedly occur in the oral cavity. It is prevalent in developed countries, occurring in all ages, geographic regions and races and about 80% of people have one episode of oral aphthous ulcers before the age of 30 years. With no laboratory procedures to confirm the diagnosis, treatment is mainly empirical in nature and focuses on short-term symptomatic management. Although numerous treatment modalities have been recommended, only a few are evidence based and can be considered for the optimal management of RAS...
October 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27888159/transmembrane-tnf-alpha-reverse-signaling-leading-to-tgf-beta-production-is-selectively-activated-by-tnf-targeting-molecules-therapeutic-implications
#11
REVIEW
Zsuzsa Szondy, Anna Pallai
Tumor necrosis factor (TNF)-α is a potent pro-inflammatory cytokine exerting pleiotropic effects on various cell types. It is synthesized in a precursor form called transmembrane TNF-α (mTNF-α) which, after being processed by metalloproteinases, is released in a soluble form to mediate its biological activities through Type 1 and 2 TNF receptors in TNF receptor expressing cells. In addition to acting in soluble form, TNF-α also acts in the transmembrane form both as a ligand by activating TNF receptors, as well as a receptor that transmits outside-to-inside (reverse) signals back into mTNF-α bearing cells...
November 22, 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/27886802/advancements-in-the-management-of-uveitis
#12
REVIEW
Sergio Schwartzman
Uveitis may exist as a clinical manifestation of an underlying systemic disease or may represent an idiopathic entity, sometimes with a very characteristic pattern. Different forms of uveitis have been defined on the basis of three important variables: chronicity, anatomic location, and underlying etiology. The evolving understanding of the immune system has resulted in a more targeted approach to manage patients with different forms of uveitis, although clearly this approach is at a very early stage. Altered patterns of cellular processing and different cytokine expression, including TNF, IL-1, IL-2, IL-6, and IL17, have been defined in uveitis, and this has laid the pathway for targeted therapy...
April 2016: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/27885553/biosimilars-for-the-treatment-of-chronic-inflammatory-diseases-a-systematic-review-of-published-evidence
#13
REVIEW
Ira Jacobs, Danielle Petersel, Leah Isakov, Sadiq Lula, K Lea Sewell
BACKGROUND: Clinicians are required to assimilate, critically evaluate, and extrapolate information to support appropriate use of biosimilars across indications. OBJECTIVES: The objective of this study was to systematically collate all published data in order to assess the weight (quantity and quality) of available evidence for each molecule and inform and support healthcare decision-making in chronic inflammatory diseases. METHODS: MEDLINE(®), EMBASE(®), and ISI Web of Science(®) were searched to September 2015...
December 2016: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/27885420/erratum-to-effectiveness-of-adalimumab-for-the-treatment-of-ulcerative-colitis-in-clinical-practice-comparison-between-anti-tumour-necrosis-factor-na%C3%A3-ve-and-non-na%C3%A3-ve-patients
#14
Marisa Iborra, Javier P Gisbert, Marta Maia Bosca-Watts, Alicia López-García, Valle García-Sánchez, Antonio López-Sanromán, Esther Hinojosa, Lucía Márquez, Santiago García-López, María Chaparro, Montserrat Aceituno, Margalida Calafat, Jordi Guardiola, Blanca Belloc, Yolanda Ber, Luis Bujanda, Belén Beltrán, Cristina Rodríguez-Gutiérrez, Jesús Barrio, José Luis Cabriada, Montserrat Rivero, Raquel Camargo, Manuel van Domselaar, Albert Villoria, Hugo Salata Schuterman, David Hervás, Pilar Nos
No abstract text is available yet for this article.
November 24, 2016: Journal of Gastroenterology
https://www.readbyqxmd.com/read/27884074/lc-ms-ms-strategies-for-therapeutic-antibodies-and-investigation-into-the-quantitative-impact-of-antidrug-antibodies
#15
Matthew Ewles, Ranbir Mannu, Chris Fox, Johannes Stanta, Graeme Evans, Lee Goodwin, James Duffy, Len Bell, Sian Estdale, David Firth
AIM: We aimed to establish novel, high-throughput LC-MS/MS strategies for quantification of monoclonal antibodies in human serum and examine the potential impact of antidrug antibodies. METHODOLOGY: We present two strategies using a thermally stable immobilized trypsin. The first strategy uses whole serum digestion and the second introduces Protein G enrichment to improve the selectivity. The impact of anti-trastuzumab antibodies on the methods was tested. CONCLUSION: Whole serum digestion has been validated for trastuzumab (LLOQ 0...
December 2016: Bioanalysis
https://www.readbyqxmd.com/read/27883347/-adalimumab-as-induction-therapy-for-crohn-s-disease-one-center-study
#16
Maciej Gonciarz, Aldona Mularczyk, Dawid Szkudłapski, Iwona Piątek, Marek Kopała
: Adalimumab is a subcutaneously administered recombinant fully human monoclonal antibody targeting tumor necrosis factor alpha. It has been approved for use in Poland to treat patients with Crohn's disease under the program of Polish National Health Found since 2010. AIM: The aim of this study was to evaluate the efficacy of adalimumab monotherapy for inducing clinical remission in patients with active Crohn's disease . The primary outcome assessment was the reduction in score to 150 or below on the Crohn's Disease Activity Index (CDAI) at 12 weeks and the secondary one was the reduction in ΔCDAI of at least 100 points...
November 25, 2016: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/27883215/effects-of-concomitant-immunomodulators-on-the-pharmacokinetics-efficacy-and-safety-of-adalimumab-in-patients-with-crohn-s-disease-or-ulcerative-colitis-who-had-failed-conventional-therapy
#17
J-F Colombel, B Jharap, W J Sandborn, B Feagan, L Peyrin-Biroulet, S F Eichner, A M Robinson, N M Mostafa, Q Zhou, R B Thakkar
BACKGROUND: Adalimumab is approved for use in patients with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) who have not achieved disease control with conventional therapies including corticosteroids and/or immunomodulators (IMM). AIM: To analyse six studies that examined efficacy, pharmacokinetics and safety of combination IMM/adalimumab therapy, compared with adalimumab monotherapy in patients with inadequate disease control on conventional therapy...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27882833/evaluation-of-real-world-experience-with-tofacitinib-compared-with-adalimumab-etanercept-and-abatacept-in-ra-patients-with-1-previous-biologic-dmard-data-from-a-u-s-administrative-claims-database
#18
James Harnett, Robert Gerber, David Gruben, Andrew S Koenig, Connie Chen
BACKGROUND: Real-world data comparing tofacitinib with biologic disease-modifying antirheumatic drugs (bDMARDs) are limited. OBJECTIVE: To compare characteristics, treatment patterns, and costs of patients with rheumatoid arthritis (RA) receiving tofacitinib versus the most common bDMARDs (adalimumab [ADA], etanercept [ETN], and abatacept [ABA]) following a single bDMARD in a U.S. administrative claims database. METHODS: This study was a retrospective cohort analysis of patients aged ≥ 18 years with an RA diagnosis (ICD-9-CM codes 714...
December 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27881258/cost-effectiveness-analysis-of-tocilizumab-in-comparison-with-infliximab-in-iranian-rheumatoid-arthritis-patients-with-inadequate-response-to-tdmards-a-multistage-markov-model
#19
Amir Hashemi-Meshkini, Shekoufeh Nikfar, Elizabeth Glaser, Ahmadreza Jamshidi, Seyed Alireza Hosseini
OBJECTIVES: To analyze the cost-effectiveness of two common treatment strategies in Iran, comparing infliximab plus methotrexate with tocilizumab plus methotrexate in patients with rheumatoid arthritis with inadequate response to traditional disease-modifying antirheumatic drugs. METHODS: A multistage Markov decision model was applied to assess the incremental cost-effectiveness ratio (ICER) of a tocilizumab-containing regimen versus an infliximab-containing regimen over a 5-year time period...
May 2016: Value in Health Regional Issues
https://www.readbyqxmd.com/read/27881144/comparison-of-treatment-response-remission-rate-and-drug-adherence-in-polyarticular-juvenile-idiopathic-arthritis-patients-treated-with-etanercept-adalimumab-or-tocilizumab
#20
Gerd Horneff, Ariane Klein, Jens Klotsche, Kirsten Minden, Hans-Iko Huppertz, Frank Weller-Heinemann, Jasmin Kuemmerle-Deschner, Johannes-Peter Haas, Anton Hospach
BACKGROUND: Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab, etanercept, or tocilizumab were analyzed in clinical practice. METHODS: Data collected in the German BIKER registry were analyzed in patients with polyJIA who started treatment with approved biologics, adalimumab, etanercept or tocilizumab, from 2011 to 2015. Baseline patient characteristics, treatment response, safety and drug survival were compared...
November 24, 2016: Arthritis Research & Therapy
keyword
keyword
1884
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"